 |
21 Diseases |  |
0 Trials |
|
0 Trials |  |
57 News |  |
- || Review, Journal: Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials. (Pubmed Central) - Aug 30, 2023
AT2R antagonism, AAK1 inhibition, LANCL activation and NGF inhibition are considered first-in-class analgesics. Hopefully, these trials will result in a better clinical management of PHN.
- || Review, Journal: Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis. (Pubmed Central) - May 29, 2022
Anti-nerve growth factor (anti-NGF) agents were also reviewed, including tanezumab, which showed both positive and negative efficacy results compared to placebo, and fulranumab, the study of which was discontinued owing to adverse events. In summary, monoclonal antibody therapy remains to be further researched in order for it to be proposed as a promising future treatment option for PBS/IC.
- Clinical efficacy and safety of monoclonal antibody against Nerve Growth Factor and Fibroblast Growth Factor-18 therapy of osteoarthritis (Poster View 8) - May 6, 2022 - Abstract #EULAR2022EULAR_2523;
Based on the results of current research findings, NGF inhibitors relieved pain and enhance joint function and may be considered as the most effective for functional improvement. FGF-18 decrease the cartilage loss and may improve cartilage thickness.
- || pregabalin / Generic mfg., gabapentin / Generic mfg., duloxetine / Generic mfg.
Retrospective data, Review: Different Drugs for the Treatment of Painful Diabetic Peripheral Neuropathy: A Meta-Analysis. (Pubmed Central) - Nov 17, 2021
In addition, the efficacy of buprenorphine, tanezumab, fulranumab and others could not be concluded due to insufficient studies...For the results of our meta-analysis, long-term studies are still needed to verify their efficacy and safety in the future. Systematic Review Registration: PROSPERO, identifier: CRD42020197397.
- || fulranumab (AMG-403) / Amgen
Clinical, P2 data, Journal: Fulranumab as Adjunctive Therapy for Cancer-Related Pain: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. (Pubmed Central) - Aug 11, 2020
P2
REGISTRATION: ClinicalTrials.gov identifier: NCT00929188 PERSPECTIVE: Efficacy and safety of fulranumab as adjunctive pain therapy in terminally-ill cancer patients were assessed. Results suggest that anti-NGF agents may prove to be novel additions in helping to optimize pain relief in cancer patients who fail to respond adequately to opioids and other common co-analgesics.
- ||| fulranumab (AMG-403) / Amgen
Clinical, P3 data, Journal: Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies. (Pubmed Central) - Jul 11, 2020
P3
Within the limited sample analyzed, fulranumab showed evidence of improvement of pain and function in patients with moderate-to-severe osteoarthritis who had failed prior therapy and were candidates for joint replacement surgery. Fulranumab as adjuvant or monotherapy was well tolerated with no new safety signals Fulranumab demonstrated evidence suggestive of efficacy in osteoarthritic pain of hip and knee Fulranumab demonstrated evidence suggestive of improvement of pain and physical function in osteoarthritis.
- || Botox (onabotulinumtoxin A) / GSK, AbbVie
Clinical, Journal: Emerging therapies in clinical development and new contributions for neuropathic pain. (Pubmed Central) - May 23, 2020
New drugs that act on different therapeutic targets are currently in preclinical development or in their first phases of clinical development. In this review, focus will be directed specifically on new pharmacological treatments for neuropathic pain for which clinical data are already available, including older and known drugs with new data on their anti-neuropathic activity.
- || fulranumab (AMG-403) / Amgen
Clinical, Journal: Evaluation of the Toxicity and Neurological Effects of Fulranumab in Adult Cynomolgus Monkeys. (Pubmed Central) - Jan 27, 2020
Fulranumab did not cause any neuronal death, necrosis, apoptosis, or any apparent decrease in function of sympathetic neurons/ganglia at any time point examined. A no observed effect level (NOEL) was established at 0.25 mg/kg fulranumab SC every 4 weeks for 28 weeks.
- ||||||| fulranumab (AMG-403) / Amgen
Trial completion: Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007 (clinicaltrials.gov) - Oct 17, 2016
P3, N=111, Completed, Sponsor: Janssen Research & Development, LLC
A no observed effect level (NOEL) was established at 0.25 mg/kg fulranumab SC every 4 weeks for 28 weeks. Active, not recruiting --> Completed
- || fulranumab (AMG-403) / Amgen
Trial completion, Monotherapy: Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003 (clinicaltrials.gov) - Oct 17, 2016
P3, N=41, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || fulranumab (AMG-403) / Amgen
Trial completion, Monotherapy: Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002 (clinicaltrials.gov) - Oct 13, 2016
P3, N=18, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| fulranumab (AMG-403) / Amgen
Trial completion: Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001 (clinicaltrials.gov) - Oct 13, 2016
P3, N=79, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | fulranumab (AMG-403) / Amgen
Enrollment change, Monotherapy: Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002 (clinicaltrials.gov) - May 24, 2016
P3, N=18, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed N=450 --> 18
- ||||| fulranumab (AMG-403) / Amgen
Enrollment change, Trial primary completion date: Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001 (clinicaltrials.gov) - May 24, 2016
P3, N=79, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
N=450 --> 18 N=450 --> 79 | Trial primary completion date: May 2017 --> Sep 2016
- ||||| fulranumab (AMG-403) / Amgen
Enrollment change: Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007 (clinicaltrials.gov) - May 24, 2016
P3, N=111, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
N=450 --> 79 | Trial primary completion date: May 2017 --> Sep 2016 N=900 --> 111
- | fulranumab (AMG-403) / Amgen
Enrollment change, Monotherapy: Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003 (clinicaltrials.gov) - May 24, 2016
P3, N=41, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
N=900 --> 111 N=450 --> 41
- ||||| fulranumab (AMG-403) / Amgen
Enrollment closed, Monotherapy: Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002 (clinicaltrials.gov) - Apr 22, 2016
P3, N=450, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
N=450 --> 41 Recruiting --> Active, not recruiting
- ||||| fulranumab (AMG-403) / Amgen
Enrollment closed: Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001 (clinicaltrials.gov) - Apr 22, 2016
P3, N=450, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| fulranumab (AMG-403) / Amgen
Enrollment closed: Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007 (clinicaltrials.gov) - Apr 22, 2016
P3, N=900, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| fulranumab (AMG-403) / Amgen
Enrollment closed, Monotherapy: Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003 (clinicaltrials.gov) - Apr 22, 2016
P3, N=450, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| fulranumab (AMG-403) / Amgen
Trial primary completion date: Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001 (clinicaltrials.gov) - Feb 11, 2016
P3, N=450, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2016 --> May 2017
- |||||| fulranumab (AMG-403) / Amgen
Enrollment open: Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001 (clinicaltrials.gov) - Sep 9, 2015
P3, N=450, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Nov 2016 --> May 2017 Not yet recruiting --> Recruiting
- |||||| fulranumab (AMG-403) / Amgen
Enrollment open, Monotherapy: Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002 (clinicaltrials.gov) - Jul 25, 2015
P3, N=450, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| fulranumab (AMG-403) / Amgen
Trial completion: A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain (clinicaltrials.gov) - Apr 23, 2015
P2, N=100, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||| fulranumab (AMG-403) / Amgen
Enrollment open, Monotherapy: Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003 (clinicaltrials.gov) - Apr 14, 2015
P3, N=450, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||| fulranumab (AMG-403) / Amgen
Enrollment open: Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007 (clinicaltrials.gov) - Apr 8, 2015
P3, N=900, Recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| fulranumab (AMG-403) / Amgen
New P1 trial: A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject (clinicaltrials.gov) - Jan 28, 2015
P1, N=51, Completed, Sponsor: Amgen
- |||||||||| fulranumab (AMG-403) / Amgen
New P3 trial, Monotherapy: Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002 (clinicaltrials.gov) - Jan 13, 2015
P3, N=450, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- |||||||||| fulranumab (AMG-403) / Amgen
New P3 trial: Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001 (clinicaltrials.gov) - Jan 13, 2015
P3, N=450, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- | fulranumab (AMG-403) / Amgen
New P1 trial: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain (clinicaltrials.gov) - Dec 19, 2014
P1, N=24, Completed, Sponsor: Amgen
- |||||||||| fulranumab (AMG-403) / Amgen
New P3 trial: Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007 (clinicaltrials.gov) - Nov 25, 2014
P3, N=900, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- |||||||||| fulranumab (AMG-403) / Amgen
New P3 trial, Monotherapy: Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003 (clinicaltrials.gov) - Nov 13, 2014
P3, N=450, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- ||| fulranumab (AMG-403) / Amgen
Enrollment closed: A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain (clinicaltrials.gov) - Jan 15, 2014
P2, N=100, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- fulranumab (AMG-403) / Amgen
Enrollment change, Monotherapy: A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis (clinicaltrials.gov) - Feb 12, 2012
P2, N=196, Terminated, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting --> Active, not recruiting N=300 --> 196
- | fulranumab (AMG-403) / Amgen
Trial termination: A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia) (clinicaltrials.gov) - Aug 31, 2011
P2, N=112, Terminated, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
N=300 --> 196 Suspended --> Terminated; Logistic reasons associated with the FDA-imposed clinical hold.
- fulranumab (AMG-403) / Amgen
Enrollment change: A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia) (clinicaltrials.gov) - Aug 31, 2011
P2, N=112, Terminated, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Suspended --> Terminated; Logistic reasons associated with the FDA-imposed clinical hold. N=200 --> 112
- fulranumab (AMG-403) / Amgen
Trial termination: A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain (clinicaltrials.gov) - Aug 28, 2011
P2, N=31, Terminated, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
N=200 --> 112 Suspended --> Terminated; Logistic reasons associated with the FDA-imposed clinical hold.
- fulranumab (AMG-403) / Amgen
Enrollment change: A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain (clinicaltrials.gov) - Aug 28, 2011
P2, N=31, Terminated, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Suspended --> Terminated; Logistic reasons associated with the FDA-imposed clinical hold. N=70 --> 31
- | fulranumab (AMG-403) / Amgen
Trial termination: A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain (clinicaltrials.gov) - Aug 24, 2011
P2, N=389, Terminated, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
N=70 --> 31 Active, not recruiting --> Terminated; Based on lack of efficacy in PAI2003, sponsor made the decision to discontinue the trial.
- | fulranumab (AMG-403) / Amgen
Trial termination: A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain (clinicaltrials.gov) - Aug 23, 2011
P2, N=467, Terminated, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Active, not recruiting --> Terminated; Based on lack of efficacy in PAI2003, sponsor made the decision to discontinue the trial. Suspended --> Terminated; Logistic reasons associated with the FDA-imposed clinical hold.
- | fulranumab (AMG-403) / Amgen
Trial termination, Monotherapy: A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis (clinicaltrials.gov) - Aug 15, 2011
P2, N=196, Terminated, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Suspended --> Terminated; Logistic reasons associated with the FDA-imposed clinical hold. Suspended --> Terminated; Logistic reasons associated with the FDA-imposed clinical hold.
- | fulranumab (AMG-403) / Amgen
Trial termination: A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy (clinicaltrials.gov) - Aug 15, 2011
P2, N=77, Terminated, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Suspended --> Terminated; Logistic reasons associated with the FDA-imposed clinical hold. Suspended --> Terminated; Logistic reasons associated with the FDA-imposed clinical hold.